[HTML][HTML] Expression of FGD3 gene as prognostic factor in young breast cancer patients

…, S Bianchi, V Vezzosi, J Nori, E Vanzi, K Tavella… - Scientific reports, 2019 - nature.com
The FGD3 gene works as a cell migration inhibitor and seems to be a promising indicator of
outcome in some human cancers including breast. In this study, we analysed for the first time …

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer

T Susini, B Berti, C Carriero, K Tavella… - OncoTargets and …, 2014 - Taylor & Francis
Purpose Anthracyclines and taxanes are considered the standard for neoadjuvant chemotherapy
of breast cancer, although they are often associated with serious side effects and wide …

Ovarian cancer initially presenting as intramammary metastases and mimicking a primary breast carcinoma: a case report and literature review

…, C Molino, F Castiglione, K Tavella… - Journal of Women's …, 2010 - liebertpub.com
Background: Ovarian cancer usually spreads intra-abdominally. Supradiaphragmatic
metastases are rare, and axillary lymph node metastases are exceptional. Here, we present the …

Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin

K Tavella, A Villanucci, L Vannini, D Lavacchi… - Anti-Cancer …, 2017 - journals.lww.com
Leiomyosarcomas represent the most common variant of uterine sarcomas, and are also
considered to be the least chemosensitive. To date, adriamycin and ifosfamide are believed to …

Prognostic Role of Tumor Size Reduction> 50% after Neoadjuvant Chemotherapy for Breast Cancer

M Giani, K Tavella, I Renda, E Tartarotti, J Nori… - Journal of Cancer …, 2022 - flore.unifi.it
Purpose: We evaluated the efficacy of neoadjuvant chemotherapy in reducing locally
advanced and early breast cancers size, improving breastconserving surgery rates and its long-…

Long-term results after neoadjuvant chemotherapy for breast cancer: A single-center experience

M Giani, I Renda, A Vallario, K Tavella… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: We evaluated the efficacy of neoadjuvant chemotherapy (NACT) in reducing
locally-advanced breast cancer (LABC) size, thus improving breast-conserving surgery (…

[HTML][HTML] Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors

A Villanucci, K Tavella, L Vannini… - Molecular and …, 2018 - spandidos-publications.com
The majority of patients with ovarian cancer will experience relapse and thus require second‑line
therapy. While platinum-based therapies are the primary treatments for refractory …

Raccomandazioni cliniche per il carcinoma mammario

…, T Angiolo, T Lucia, T Roberto, T Gina, T Ketty… - … cliniche per i principali …, 2005 - flore.unifi.it
… ; Grechi Elisa; Grechi Morando; Greco Carlo; Herd-Smith Andrea; Iacconi Chiara; Lambruschi
Giorgio; Lazzeri Elena; Livi Lorenzo; Lombardi Cristina; Magnanini Simonetta; Manai Salvatore; …

[PDF][PDF] Evolution of Adjuvant Chemotherapy for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and Trastuzumab, Between 2000 and …

T Susini, A Vallario, K Tavella, A Villanucci… - WORLD JOURNAL OF …, 2019 - flore.unifi.it
… Vallario A, Susini T, Tavella K, Villanucci A, Nori J. Evolution of Adjuvant Chemotherapy
for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and …

[HTML][HTML] Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist …

N Staropoli, E Geuna, G Rinaldi, G Bisagni, V Scotti… - Current …, 2022 - mdpi.com
… We would like to express our gratitude to all patients and physicians who participated in
the MAP: Ketty Tavella, Andrea Milani, Francesca Vignani, Veronica Prati, Cristina Falci, …